ALPS Advisors’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-255,618
| Closed | -$3.7M | – | 1191 |
|
|
2026
Q1 | $3.7M | Buy |
255,618
+2,784
| +1% | +$39.9K | 0.02% | 301 |
|
|
2025
Q4 | $3.6M | Buy |
252,834
+104,781
| +71% | +$1.03M | 0.02% | 300 |
|
|
2025
Q3 | $1.17M | Sell |
148,053
-18,022
| -11% | -$128K | 0.01% | 483 |
|
|
2025
Q2 | $952K | Sell |
166,075
-56,173
| -25% | -$363K | 0.01% | 512 |
|
|
2025
Q1 | $1.81M | Sell |
222,248
-19,367
| -8% | -$179K | 0.01% | 361 |
|
|
2024
Q4 | $2.28M | Buy |
241,615
+14,562
| +6% | +$151K | 0.01% | 327 |
|
|
2024
Q3 | $2.42M | Sell |
227,053
-3,984
| -2% | -$43.4K | 0.02% | 326 |
|
|
2024
Q2 | $2.29M | Buy |
+231,037
| New | +$2.37M | 0.02% | 318 |
|
|
2023
Q4 | – | Sell |
-211,895
| Closed | -$2.58M | – | 980 |
|
|
2023
Q3 | $2.58M | Buy |
211,895
+2,716
| +1% | +$35K | 0.02% | 287 |
|
|
2023
Q2 | $2.63M | Buy |
+209,179
| New | +$2.48M | 0.02% | 266 |
|
|
2022
Q4 | – | Sell |
-153,069
| Closed | -$1.6M | – | 1051 |
|
|
2022
Q3 | $1.6M | Sell |
153,069
-13,128
| -8% | -$146K | 0.02% | 353 |
|
|
2022
Q2 | $1.78M | Sell |
166,197
-121,599
| -42% | -$1M | 0.02% | 341 |
|
|
2022
Q1 | $2.73M | Sell |
287,796
-34,672
| -11% | -$325K | 0.03% | 173 |
|
|
2021
Q4 | $3.73M | Sell |
322,468
-4,242
| -1% | -$47.3K | 0.04% | 169 |
|
|
2021
Q3 | $3.12M | Sell |
326,710
-21,731
| -6% | -$222K | 0.03% | 215 |
|
|
2021
Q2 | $3.36M | Buy |
+348,441
| New | +$3.4M | 0.03% | 204 |
|
Other funds holding FOLD
ALPS Advisors's FOLD Position: Q2 2026 in Review
ALPS Advisors sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 255,618 shares — an estimated $3.7M sold.
ALPS Advisors first reported a position in FOLD in Q2 2021 and held it in 16 quarters. The position peaked at $3.73M in Q4 2021. 1 fund tracked by Wall St. Rank holds FOLD as of Q2 2026.
- ALPS Advisors reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- ALPS Advisors sold 255,618 Amicus Therapeutics shares in Q2 2026, an estimated $3.7M.
- ALPS Advisors first reported a position in Amicus Therapeutics in Q2 2021 and held it in 16 quarters.
- ALPS Advisors's Amicus Therapeutics position peaked at $3.73M in Q4 2021.
- 1 fund tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.